A Study of Avastin (Bevacizumab) in Combination With Gemcitabine With or Without Cisplatin in First-Line Treatment of Elderly Patients With Non-Small Cell Lung Cancer
Launched by HOFFMANN-LA ROCHE · Feb 26, 2010
Trial Information
Current as of June 24, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, \>=70 years of age;
- • inoperable, locally advanced, metastatic non-squamous non-small cell lung cancer;
- • \>=1 measurable lesion;
- • ECOG performance status 0-1.
- Exclusion Criteria:
- • neoadjuvant/adjuvant chemotherapy within 6 months prior to enrollment;
- • radical radiotherapy with curative intent within 28 days prior to enrollment;
- • history of \>=grade 2 hemoptysis in 3 months prior to enrollment;
- • evidence of CNS metastases;
- • current or recent (within 10 days of first dose of Avastin)use of aspirin (\>325 mg/day)or full dose anticoagulants or thrombolytic agents for therapeutic purposes.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Udine, , Italy
Milano, , Italy
Udine, Friuli Venezia Giulia, Italy
Catanzaro, , Italy
Novara, Piemonte, Italy
Catanzaro, Calabria, Italy
Avellino, Campania, Italy
Napoli, Campania, Italy
Aviano, Friuli Venezia Giulia, Italy
Viterbo, Lazio, Italy
Genova, Liguria, Italy
Bergamo, Lombardia, Italy
Sondrio, Lombardia, Italy
Catania, Sicilia, Italy
Lido Di Camaiore, Toscana, Italy
Ancona, Marche, Italy
Bologna, Emilia Romagna, Italy
Perugia, Umbria, Italy
Padova, Veneto, Italy
Monza, Lombardia, Italy
Roma, Lazio, Italy
Rionero In Vulture, Basilicata, Italy
Rho, Lombardia, Italy
Sondalo, Lombardia, Italy
Pesaro, Marche, Italy
Mirano, Veneto, Italy
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials